Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice

Karin M. Aberg, Katherine A. Radek, Eung-Ho Choi, Dong-Kun Kim, Marianne Demerjian, Melanie Hupe, Joseph Kerbleski, Richard L. Gallo, Tomas Ganz, Theodora Mauro, Kenneth R. Feingold, and Peter M. Elias

Introduction

Multiple converging lines of evidence suggest that psychological stress (PS), if sustained, can adversely impact critical functions such as immune surveillance (1), gastrointestinal integrity (2–4), coronary artery disease (5, 6), and wound healing (7–12). Although recent studies in both humans and experimental animals suggest that PS compromises host defenses against bacterial and viral infections (13–21), the pathogenic mechanisms remain unknown. Three potentially interconnected mechanisms have been proposed to explain the negative impact of PS on host defenses against infection and neoplasia: (a) psychoneuroimmunoendocrine dysfunction, which leads to increased proinflammatory neuropeptide and cytokine production in a manner either dependent or independent of the hypothalamic-pituitary-adrenal (HPA) axis (18–24); (b) increased plasma levels of endogenous glucocorticoid (GC) caused by activation of the HPA axis (16, 18–24); and (c) a cutaneous steroidogenic system, with localized production of corticotropin-releasing factor (CRF) (26, 27), which could mediate the adverse effects of PS on skin.

The skin is the first line of defense against microbial infection, and psychological stress (PS) has been shown to have adverse effects on cutaneous barrier function. Here we show that PS increased the severity of group A Streptococcus pyogenes (GAS) cutaneous skin infection in mice; this was accompanied by increased production of endogenous glucocorticoids (GCs), which inhibited epidermal lipid synthesis and decreased lamellar body (LB) secretion. LBs encapsulate antimicrobial peptides (AMPs), and PS or systemic or topical GC administration downregulated epidermal expression of murine AMPs cathelin-related AMP and β-defensin 3. Pharmacological blockade of the stress hormone corticotrophin-releasing factor or of peripheral GC action, as well as topical administration of physiologic lipids, normalized epidermal AMP levels and delivery to LBs and decreased the severity of GAS infection during PS. Our results show that PS decreases the levels of 2 key AMPs in the epidermis and their delivery into LBs and that this is attributable to increased endogenous GC production. These data suggest that GC blockade and/or topical lipid administration could normalize cutaneous antimicrobial defense during PS or GC increase. We believe this to be the first mechanistic link between PS and increased susceptibility to infection by microbial pathogens.

The negative consequences of PS on critical epithelial functions (in contrast to those of other tissues) such as epidermal permeability barrier homeostasis (28–30) could be ascribed largely—if not entirely—to a PS-induced increase in circulating levels of GCs, because blockade of either GC production by systemic administration of a CRF inhibitor or GC peripheral action with a GC receptor (GCr) antagonist normalizes permeability barrier function in mice subjected to multiple forms of PS (31, 32). The central role of a PS-induced increase in endogenous GCs is further supported by the observation that short-term administration of either systemic or topical GCs produces an almost-identical spectrum of epidermal abnormalities (33).

The adverse effects of PS or GC increase on cutaneous permeability barrier function can be further ascribed to an inhibition of epidermal lipid synthesis, leading to decreased production of epidermal lamellar bodies (LBs) (33, 34), multifunctional organelles that deliver endogenous lipids, desquamatory enzymes, and antimicrobial peptides (AMPs) to the stratum corneum (SC) interstices, thereby providing for the permeability and antimicrobial barriers (35, 36). As noted above, LBs in human epidermis encapsulate and secrete not only lipids, but also at least 2 AMPs, β-defensin (hBD2) and the cathelicidin hCap18 carboxytential fragment LL-37 (37, 38). Because our prior studies showed that protein delivery to nascent epidermal LBs is dependent upon prior or concurrent deposition of lipids within this organelle (39), we hypothesized that PS, by inhibiting epidermal lipid synthesis and

Nonstandard abbreviations used: AMP, antimicrobial peptide; CRAMP, cathelin-related AMP; CRF, corticotropin-releasing factor; GAS, group A Streptococcus pyogenes; GC, glucocorticoid; GCr, GC receptor; HPA, hypothalamic-pituitary-adrenal; LB, lamellar body; mBD, mouse β-defensin; PS, psychological stress; SC, stratum corneum.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J. Clin. Invest. 117:3339–3349 (2007). doi:10.1172/JCI31726.
we hypothesized further that if the putative link between PS and effects of PS or GC increase on epidermal lipid synthesis and LB mediated by an increase in endogenous GC. This decrease in AMP could also restore production/bioavailability of one or both AMPs. Our studies determined that PS decreases levels of 2 key AMPs in the epidermis by divergent mechanisms, both ultimately mediated by an increase in endogenous GC. This decrease in AMP increased the severity of cutaneous GAS infections, and GC blockade and/or topical physiologic lipids could normalize epidermal antimicrobial defense in the face of PS/GC. Finally, we demonstrated that physiologic GC account for the low, constitutive expression of these AMP under nonstressed conditions.

Results

PS downregulates murine epidermal cathelicidin and mouse β-defensin 3 (mBD3) protein levels by divergent mechanisms. To ascertain whether PS modulates epidermal AMP levels, we first assessed cathelicidin and mBD3 protein levels both in epidermis and in pilosebaceous epithelia. As with PS, exogenous GCs downregulate epidermal AMP expression. To test whether the negative effects of PS can be attributed to increased endogenous GCs, we initially ascertained whether supraphysiologic doses of systemic or topical GCs downregulate epidermal AMP production. For the studies with systemic GCs, we administered 450 μg/kg dexamethasone intraperitoneally to hairless mice 3 times over 72 h, a dose previously shown to compromise epidermal differentiation, proliferation, lipid synthesis, and permeability barrier function (32–34). Whereas intraperitoneal administration of vehicle alone to normal mice (Figure 2, B and E) did not alter either CRAMP or mBD3 levels compared with untreated controls (Figure 2, A and D), systemic GCs markedly downregulated immunostaining for CRAMP and mBD3 protein levels both in epidermis and in pilosebaceous structures (Figure 2, C and F, asterisks).

Figure 1

PS downregulates epidermal AMP expression. Normal hairless mice (n = 3 each for immunohistochemistry and RT-PCR studies; 3–4 replications for each experiment in these and subsequent experiments) were exposed to insomnia- and crowding-induced PS (B and E) for 72 h, while littermate controls (A and D) were not stressed. Frozen sections (8 μm) were stained with primary antibodies to CRAMP and mBD3 and processed as described in Methods (for controls, see Supplemental Figure 1).

As with PS, exogenous GCs downregulate epidermal AMP expression. To test whether the negative effects of PS can be attributed to increased endogenous GCs, we initially ascertained whether supraphysiologic doses of systemic or topical GCs downregulate epidermal AMP production. For the studies with systemic GCs, we administered 450 μg/kg dexamethasone intraperitoneally to hairless mice 3 times over 72 h, a dose previously shown to compromise epidermal differentiation, proliferation, lipid synthesis, and permeability barrier function (32–34). Whereas intraperitoneal administration of vehicle alone to normal mice (Figure 2, B and E) did not alter either CRAMP or mBD3 levels compared with untreated controls (Figure 2, A and D), systemic GCs markedly downregulated immunostaining for CRAMP and mBD3 protein levels both in epidermis and in pilosebaceous structures (Figure 2, C and F, asterisks).
edly declined after 3 applications of topical clobetasol over a 72-h time period (Figure 3). Finally, in contrast to both PS and systemic GCs, topical GCs did not appear to reduce immunostaining for AMPs in pilosebaceous structures (Figure 3, B and D, asterisks). However, because these hairless mice have less prominent pilosebaceous ducts, it is possible that clobetasol would suppress AMP production within follicles of hairy mice.

Finally, to clarify further whether the PS-induced increase in endogenous GCs inhibits AMP expression at the mRNA or protein level, we next added dexamethasone (10 nM) to second-passage cultured human keratinocytes. Whereas keratinocyte mRNA levels for LL-37 (the cathelicidin human homolog) declined in response to dexamethasone treatment, mRNA levels for hBD2 (the human homolog of mBD3) did not change (Supplemental Figure 2). Together, these results further suggest that GCs regulate CRAMP/LL-37 mRNA and protein expression, while hBD2/mBD3 is regulated at the protein level alone.

PS-induced AMP downregulation is mediated by increased endogenous GCs. Prior studies have demonstrated that a PS-induced increase in endogenous GCs largely accounts for the negative effects of PS on epidermal structure and function (31, 32, 34). To assess whether a PS-induced increase in endogenous GCs also accounts for the PS-induced decline in AMP levels, we first assessed whether RU-486, a broad-spectrum GC blocker, would restore epidermal GC peripheral action by systemic administration of mBD3 (see Methods). Scale bar: 50 μm.

In mice subjected to mBD3, LBs not only were reduced in number (see below), but also demonstrated little or no immunolabeling for either CRAMP or mBD3 (Figure 5, A and B). Where labeling was present in PS mice, it was scattered instead at low levels throughout the cytosol of stratum granulosum cells (Figure 5, A and B, circles). In contrast, when PS mice were cotreated with RU-486, many LBs again demonstrated immunolabeling of both AMPs within their internal contents. Finally, we quantified the extent of LB immunolabeling for CRAMP and mBD3 in randomized, coded biopsies (Figure 4, A and D, circles). Biopsies were obtained for immunostaining for CRAMP and mBD3 (see Methods). Scale bar: 50 μm.

CRF intraperitoneally to block GC production. Like RU-486, antalarmin cotreatment again appeared to normalize or supernormalize both mBD3 and CRAMP immunostaining in the face of ongoing PS (Figure 4, compare D and H with A and E). Finally, antalarmin also increased AMP immunostaining in pilosebaceous structures (Figure 4, D and H, asterisks). Together, these results strongly suggest that the adverse effects of PS on epidermal and pilosebaceous AMP production can be attributed to an increase in endogenous GC production and/or peripheral action.

PS-induced downregulation of AMP delivery to epidermal LBs is reversed by GC blockade. As described above, the human homologs of CRAMP and mBD3 (LL-37 and hBD2, respectively) are sequestered within epidermal LBs in preparation for their putative secretion into the SC interstitium. We next used immuno electron microscopy to ask whether PS alters the loading of mouse AMPs into nascent LBs. In mice subjected to mice, LBs not only were reduced in number (see below), but also demonstrated little or no immunolabeling for either CRAMP or mBD3 (Figure 5, A and B). Where labeling was present in PS mice, it was scattered instead at low levels throughout the cytosol of stratum granulosum cells (Figure 5, A and B, circles). In contrast, when PS mice were cotreated with RU-486, many LBs again demonstrated immunolabeling of both AMPs within their internal contents. Finally, we quantified the extent of LB immunolabeling for CRAMP and mBD3 in randomized, coded biopsies (Figure 4, A and D, circles). Biopsies were obtained for immunostaining for CRAMP and mBD3 (see Methods). Scale bar: 50 μm.
expression of these AMPs can be attributed to physiologic levels or became supernormal in PS mice cotreated with RU-486 (Figure 5, C and D). Together, these results demonstrate first, by an alternate method, that PS reduces production and/or delivery of AMPs, and second, that such reduced delivery to LB reflects a PS-induced increase in endogenous GCs.

Endogenous GCs account for low constitutive levels of AMP production in normal epidermis. Because both hBD2 and cathelicidin demonstrate low, constitutive expression in normal human epidermis (40, 41), and because blockade of endogenous GCs in PS mice resulted in supernormal AMP immunostaining, we next asked whether the low expression of these AMPs can be attributed to physiologic levels of endogenous GCs. Indeed, both RU-486 and antalarmin treatment increased immunostaining for mBD3 and CRAMP in normal murine epidermis (Figure 6, A–C and E–G). Moreover, blockade in the production and/or action of endogenous GCs also increased immunostaining for both AMPs in pilosebaceous structures (Figure 6, B, C, F, and G, arrows). Furthermore, epidermal immunostaining for CRAMP and mBD3 increased markedly in adrenalectomized mice (differences for CRAMP were more striking than for mBD3; Figure 6, D, H, I, and J), as did immunostaining of both AMPs in pilosebaceous follicles (Figure 6, D and H, arrows). Yet, despite the adverse effects of excess GCs on epidermal structure and function (see above), adrenalectomy did not improve epidermal permeability barrier homeostasis (Supplemental Figure 3). These results strongly suggest that the low constitutive expression of mBD3 and CRAMP in epidermis and appendages can be attributed to physiologic levels of endogenous GCs, but such physiologic levels of GCs do not alter cutaneous permeability homeostasis.

Exogenous lipids override the negative effects of PS and GCs on mBD3, but not CRAMP, expression and delivery to LB. Topical replacement of the 3 inhibited lipids (cholesterol, ceramides, and free fatty acids) reverses PS- or GC-induced abnormalities in epidermal LB production (33, 34) (Supplemental Figure 4), and protein delivery to LB is dependent upon prior and/or concurrent lipid deposition within these organelles (39). Hence, we next asked whether coadministration of a mixture of ceramides, cholesterol, and free fatty acids at a 1:1:1 molar ratio, designed to correct the PS- or GC-induced inhibition of epidermal lipid synthesis (33, 34), normalizes AMP production in the face of PS. Both PS and GCs again downregulated mBD3 and CRAMP protein levels (Figure 7, A, B, D, and E, and Supplemental Figure 5). As previously described (33, 34), the topical lipid mixture normalized both the density (i.e., production) of LB and the LB content in the face of PS or topical GC therapy (Supplemental Figure 4). Yet, while the coapplied lipid mixture partially normalized mBD3 immunolabeling in the face of both PS and topical GCs (Figure 7, C and F), it failed to increase CRAMP immunolabeling under the same conditions (Supplemental Figure 5), effectively ruling out the possibility that the lipids could be interfering with GC uptake. Furthermore, as noted above, topical lipid treatment of PS animals increased mBD3, but not CRAMP, uptake into epidermal LBs (Figure 5, A, B, E, and F). Finally, the topical lipids did not reverse the PS-induced decline in either CRAMP or mBD3 immunostaining of pilosebaceous structures (Figure 7, C and F, arrows, and Supplemental Figure 5). These results show that topical lipid replacement partially normalized the epidermal protein levels of mBD3 as well as the deposition of this AMP within epidermal LBs, consistent with posttranscriptional regulation of expression of this AMP by PS or GCs. Conversely, lipid replacement increased neither CRAMP protein levels nor deposition in LB, consistent with regulation of this AMP by PS or GCs instead at a transcriptional level.

PS-induced decline in epidermal AMPs correlates with increased susceptibility to cutaneous infections and is mediated by GCs. Prior studies have shown that CRAMP knockout mice exhibit increased susceptibility to group A Streptococcus pyogenes (GAS) skin infections (42).

Figure 4
PS-induced downregulation of epidermal AMPs is reversed by blockade of endogenous GC production and/or action. Hairless mice (n = 3 per group) were exposed to PS with concurrent intraperitoneal administration of either RU-486 (C and G), antalarmin (ant; D and H), or vehicle (B and F). For dosage, timing, and drug concentrations, see Methods. Frozen sections (8 μm) were immunostained with CRAMP (A–D) or mBD3 (E–H) primary antibodies (see Methods). Samples A and E were from untreated control littermates. Scale bar: 50 μm.
Because PS substantially reduced CRAMP levels in both epidermis and skin appendages, we next assessed directly whether PS increases the severity of cutaneous GAS infections. In nonstressed mice, skin abscesses peaked in size at 20 ± 10 mm 4 d after intracutaneous inoculation of GAS, receding to 10 ± 3 mm by 5 d (Figure 8). In PS mice, mean lesion size was almost twice that of nonstressed mice, and abscesses persisted longer. In contrast, when PS mice were cotreated with RU-486, skin abscesses were comparable in size to those of nonstressed mice (Figure 8, C and D). However, RU-486 did not decrease the severity of GAS infections in nonstressed mice. Together, these results demonstrate that the PS-induced, GC-mediated reduction in AMPs has negative consequences for resistance to cutaneous GAS infection.

Discussion

PS adversely affects the function of epithelial tissues, including the epidermis, where it perturbs both epidermal permeability barrier homeostasis (28–31) and cutaneous wound healing (1, 3, 7–12). Although PS-induced functional abnormalities (23, 43, 44) are often attributed to psychoneuroimmune abnormalities, PS-induced stimulation of endogenous GC production, which compromises both epidermal lipid synthesis and LB production, accounts for epidermal dysfunction (32–34). Because PS increases systemic GC levels and systemic administration of both the CRF inhibitor antalarmin and the GCr antagonist RU-486 completely normalize function, HPA-derived GCs are likely important mediators of the effects of PS on epidermal function. Yet the recently described cutaneous steroidogenic system (26, 27, 45, 46) could also be a participant, because the skin elaborates not only CRF (47, 48), but also corticosteroids, which are generated by different types of cells within the skin (49, 50).

We show here that PS also inhibited another key function: antimicrobial defense. Moreover, the decrease in epidermal AMP production was sufficient to increase the severity of infections from at least one important bacterial pathogen, GAS. Thus, the PS-induced decline in AMPs could account for the association between PS and...
The reported increased risk of cutaneous infections in the face of PS. Accordingly, abundant anecdotal evidence connects PS to outbreaks or progression of viral skin infections including herpes simplex, Epstein-Barr virus, HIV, influenza, and varicella/zoster virus infections (14, 16–19, 21, 25); mucosal bacterial infections such as bacterial vaginitis (51); and inflammatory dermatoses such as acne, in which microbial colonization indisputably aggravates disease expression (52). Finally, because PS exerts potent systemic effects via an increase in endogenous GCs (see below), it is highly likely that these results have implications for extracutaneous infections that occur in the face of either increased PS or systemic or topical GC therapy. Indeed, while it is generally accepted that increased endogenous GCs increase susceptibility to infection, the link to PS is more tenuous (53).

First we explored whether PS — which has well-known, adverse effects on permeability barrier homeostasis in humans and hairless mice (29, 30) — also adversely affects cutaneous AMP expression. In a well-characterized model of sustained PS (insomnia, crowding, and auditory stimulation in hairless mice; refs. 32, 34), we showed that PS downregulated the expression of both the murine cathelicidin CRAMP and the murine β-defensin mBD3. The fact that PS and GCs produce negative effects in human epidermis (29, 30, 33) comparable to those in hairless mice (32–34) validates the further use of hairless mice as a model for these studies. Nevertheless, it remains possible that some of the PS-induced effects observed here could be influenced by the absence-of-function for gene product(s), because comparable studies were not performed in normal mouse skin.

We focused here on CRAMP and mBD3 because the human homologs of these 2 AMPS are known products of the epidermal LB secretory system (37, 38), and therefore, their expression could be influenced by PS or GCs, both of which reduce LB production (33, 34). Although the constitutive expression of these peptides is reportedly low in normal epidermis (41, 54), these peptides are readily detectable in normal murine epidermis by immunofluorescence, even under basal conditions, allowing us to readily discriminate further PS-induced declines in AMP protein. While PS reduced protein levels for both CRAMP and mBD3, only CRAMP declined at the mRNA level, suggesting different levels of regulation by PS for CRAMP and mBD3 (Figure 9 and see below).

We next addressed the mechanisms whereby PS adversely alters AMP expression. Because the adverse effects of PS on epidermal permeability barrier function are mediated by increased endogenous GCs (31, 32), we hypothesized that the effects of PS on AMP production (and on increased susceptibility to skin infections) could be attributable to increased endogenous GCs. Accordingly, both systemic and topical GCs downregulated protein levels for both CRAMP and mBD3. But systemic GCs, like PS, did not reduce mRNA levels for mBD3. Pertinently, systemic GCs also downregulated NFκB-dependent expression of at least one AMP in amphibian skin (51). The PS-endogenous GC mechanism is strongly supported by the dual observations that blockade of GC increase
with systemic administration of the CRF inhibitor antalarmin and blockade of GC peripheral action with systemic administration of the GC inhibitor RU-486 both normalized AMP expression in the face of ongoing PS. The final proof of a PS-GC connection is shown by the observation that PS amplified the severity of cutaneous GAS infections, while conversely, systemic administration of RU-486 normalized resistance to this bacterial pathogen in the face of ongoing PS. Together, these studies show the important role of increased endogenous GCs in the PS-induced decline of epidermal AMP expression as well as a direct link between PS, via increased endogenous GCs, and microbial pathogenesis. Yet these studies did not address the source of the endogenous GCs that mediate the negative effects of PS on cutaneous antimicrobial defense. Increased GCs of HPA origin and/or generated within the skin (which elaborates several HP mediators, including CRF, proopiomelanocortin, and adrenocorticotropin) could, in part, account for these phenomena (27, 45, 55). Moreover, certain cell types within skin appear capable of generating GCs (49, 50, 56).

Figure 7
Coapplication of topical physiologic lipids partially normalizes mBD3 expression in the face of PS or increased GCs. Hairless mice (n = 4 or 5 per cohort) received either an equimolar mixture of ceramides, cholesterol, and free fatty acids (1:1:1 molar ratio; 2% final concentration) in propylene glycol/ethanol (7:3 v/v) vehicle (60 μl to a 3-cm² area) or vehicle alone, while being cotreated with either PS (E and F) or topical clobetasol (GC, B and C). Frozen sections were immunostained for mBD3 (see Methods). Controls treated only with vehicle are shown in A and D. Scale bars: 50 μm.

Figure 8
PS increases the severity of cutaneous GAS infection. (A) Female 8- to 10-wk-old Skh1/Hr mice were subjected to normal conditions or PS for 72 h, and then subsequently injected intradermally with 4.8 x 10⁸ CFU/ml GAS (n = 6 per group). Mice were then photographed daily for 4 d to monitor lesion size. (A) Representative lesions at day 4 from nonstressed and PS mice. (B) Lesion size (mean ± SEM) was calculated ± SEM for day 1 and day 4 lesions. *P < 0.05 versus nonstressed. (C) Representative lesions of PS mice (n = 5–6 per group) immediately prior to and 72 h after IP injection with either vehicle or RU-486 (6 mg/kg). After 72 h of PS or nonstressed conditions, mice were injected intradermally with 4.8 x 10⁸ CFU/ml GAS. A representative photograph of day 4 lesions from each group is shown. (B) Lesion size (mean ± SEM) was calculated for day 4 lesions. *P < 0.05 versus PS and RU-486; †P < 0.05 versus PS and vehicle.
Thus, GCs of HPA origin and/or originating within the cutaneous neuroendocrine system could mediate the PS-induced responses described herein.

While these results provide mechanistic insights into PS-relat ed alterations in antimicrobial defense, they also provide a likely pathomechanism for the increased risk of cutaneous (and extracutaneous) infections during PS (13, 15, 18, 20, 24) as well as both systemic and topical GC therapy (47, 48, 57, 58). It should be noted, however, that PS or GC therapy could increase the risk of cutaneous infections by other, unrelated mechanisms; for example, GCs decrease epidermal dendritic cell function (59, 60), another important participant in cutaneous innate immunity, and also decrease epidermal primary cytokine levels (33), which could influence antimicrobial defense by a variety of downstream mechanisms. Indeed, primary cytokines regulate hBD2 expression at a transcriptional level via NF-κB and AP-1 sites on the hBD2 promoter (61), and they increase hBD2 bioavailability by stimulating accumulation of nascent peptides within epidermal LB (37).

Whereas the effects of GCs (and presumably, therefore, of PS) on CRAMP protein expression can be attributed to downregulation at the mRNA level, PS and systemic GCs instead appear to decrease mBD3 expression at the protein level alone (Figure 9). The ability of topical physiologic lipids to partially override the PS-induced downregulation of mBD3 (whose mRNA levels do not change with PS) supports the concept that PS downregulates AMPs through increased endogenous GCs, which in turn inhibits epidermal lipid synthesis and/or LB formation (34). Yet adrenalectomized mice demonstrated an increase in mBD3 mRNA expression, while clobetasol treatment downregulated mRNA levels of mBD3. These divergent results can best be explained by the sustained decrease in GC production that occurs in adrenalectomized mice. Conversely, the superpotent topical steroid clobetasol likely has more profound effects on epidermal structure and metabolism than systemic GCs. Thus, the decrease in mRNA levels for mBD3 in clobetasol-treated mice likely reflects a global decrease in protein synthesis. Although the precise subcellular mechanisms whereby exogenous lipids appear to override the negative effects of PS or GC therapy on mBD3 remain uncertain, exogenous physiologic lipids have previously been shown to traverse the SC, targeting the trans-Golgi apparatus of cells in the outer nucleated layers where LBs are assembled (62, 63). Because packaging of protein cargo within LBs is dependent on prior or concurrent lipid deposition (39), addition of exogenous lipids to endogenous lipid equivalents could allow additional AMPs to be loaded into nascent LBs. Our immunoelectron-microscopic results support this scheme, because exogenous lipids clearly enhanced deposition of mBD3, but not CRAMP, within LBs in the face of ongoing PS. Not only endogenous lipids (64), but also both hBD2 and the hCAP product LL-37, are copackaged within epidermal LBs (37, 38) and then coexisting into the SC interstices (65). Our present results show that their murine homologs mBD3 and CRAMP were also assembled within epidermal LBs. Thus, the PS- and GC-induced downregulation of mBD3 expression appears to reflect a prior diminution in epider mal lipid synthesis and/or LB production (Figure 9).

One or more additional posttranscriptional mechanisms could contribute to the PS-induced decline in mBD3 protein. While physical abrogation of the epidermal permeability barrier function typically stimulates generation of IL-1α and other primary cytokines (66, 67), topical GCs instead decrease epidermal IL-1α and TNF-α expression (33). Thus, a PS- or GC-induced decline in cytokine signaling (33) could contribute to reduced mBD2 expression. Prior work has similarly suggested that a decline in primary cytokine production contributes to PS-induced delays in cutaneous wound healing (9–12, 22). Regardless of specific regulatory mechanisms, our studies suggest that exogenous physiologic lipids could benefit not only epidermal permeability barrier function in the face of PS or GCs (33, 68), but also cutaneous antimicrobial defense. The common effects of PS and GCs on epidermal function and AMP expression also support the putative link between the permeability and antimicrobial barriers in epidermis (35, 36). If operative in other epithelia, PS-induced suppression of AMPs via increased endogenous GCs could also explain the frequency and severity of infections in extraepidermal tissues of patients subjected to PS (1–10, 35, 36). Indeed, we show here that PS downregulated AMPs in pilosebaceous structures, consistent with a microbial cause for the observation that acne vulgaris flares with increased PS (49).

It is well known that PS adversely affects epithelial structure and function in gastrointestinal epithelia (2–4, 69); AMPs in these epithelia may be important not only for antimicrobial defense, but also for structural integrity (i.e., for the permeability barriers in several extracutaneous epithelia; refs. 69–75). Thus, it is likely, although not yet proven, that PS could abrogate AMP production in parallel with its ability to compromise extracutaneous epithelial barriers, as shown here for epidermis and pilosebaceous structures.

If these speculations can be validated, systematic therapy with CRF or GC inhibitors and/or targeted lipid replacement could improve clinical outcomes in these settings.

Methods

Murine stress models

Female hairless control mice (Skh1/Hr) and hairless Skh1 adrenalecto mized mice were purchased from Charles River Laboratories and studied between 7 and 9 wk of age. All animal experiments described in this study were conducted in accordance with accepted standards of humane animal care, under protocols approved by the local animal research committee at San Francisco VA Medical Center. Prior to beginning experiments, cohorts of 3 animals each were kept in separate cages for at least 7 d. For the PS group, groups of 6 animals at a time (2 cohorts) were transferred to a 12.5-cm-diameter, 12.5-cm-high, transparent glass jar and exposed to continuous visible light and radio noise for 72 h. Additional groups of PS animals were injected intraperitoneally with either RU-486 antalarmin in

Figure 9
Divergent mechanisms for PS-induced downregulation of epidermal CRAMP and mBD3.
propylene glycol/ethanol (7.3 v/v) or vehicle alone 1 h prior to stress onset and every 24 h thereafter for 72 h. RU-486 (mifepristone; Sigma-Aldrich) and antalarmin hydrochloride (Sigma-Aldrich) were administered at doses of 6 mg/kg (1 mg/ml propylene glycol) and 20 mg/kg, respectively. Additional mice were kept in ordinary cages (3 per cage), without continuous light and sound, and injected in some cases with vehicle as described above. All experimental results were replicated 2–3 times in separate experiments, and the results shown in the figures are representative of the results in replicate experiments. All mice were maintained in a temperature- and humidity-controlled room and given standard laboratory food and tap water ad libitum. There were no differences in body weights in the PS versus control groups during the course of these experiments.

**GC administration and blockade**

Female hairless mice (Skh1/Hr; 7–8 wk of age), as described above, were used for GC systemic and topical administration. Clobetasol 0.05% in propylene glycol/ethanol (7.3 v/v) was applied twice daily for 3 d to the flanks of hairless mice. Another group of littermates received vehicle alone at the same frequency. Systemic GC was administered by injecting each mouse intraperitoneally with 9 μg dexamethasone (450 μg/kg) in propylene glycol/ethanol (7.3 v/v) vehicle or vehicle alone once daily for 3 d, as described previously (31, 33). Dexamethasone (10 nm) or ethanol vehicle was added to confluently (80%–90%), second-passage, cultured human keratinocytes. mRNA was harvested 18 h later for quantitation of hBD2 and LL-37 by RT-PCR (see below).

**Tissue preparation, protein, and RNA isolation**

Skin samples were obtained following 3 d of topical or systemic GC treatment, or 72 h PS with or without RU-486 or antalarmin. Epidermis from skin of PS and nonstressed Skh1/Hr mice was injected with 50 μl of sterile Cytodex beads, which acts as a carrier, or luteinizing hormone (LH)-releasing hormone (LRH) agonist (77). mRNA was harvested 18 h later for quantitation of hBD2 and LL-37 by RT-PCR (see below).

**Western immunoblotting**

For Western blotting, a method was employed for extraction of low-molecular weight, hydrophobic, cationic peptides, as described previously (80). Briefly, epidermis was separated from mouse skin after incisions of full-thickness pieces of flank skin in 10 mM EDTA in PBS at 37°C for 2 h. Extractions were performed in an acidic buffer (30% acetonitrile, 0.1% formic acid; pH <3); extracts were homogenized on ice and centrifuged at 17,530 g for 30 min at 4°C, and then the supernatants were re-centrifuged for 15 min prior to protein fractionation. An equal amount of extracted protein in NuPAGE sample buffer in water was heated at 85°C, without reducing agents, followed by loading of equal amounts of samples from each experimental group onto 10% tricine gels (Invitrogen), using β-actin as an internal standard. After electrophoresis, proteins were transferred from gels onto PVDF membranes and electrophoresed for 1 h in tricine/glycine transfer buffer, followed by immunoblotting with the rabbit anti-mouse mBD3 antibody (Alpha Diagnostics). Antibody binding to mBD3 was detected with the Western-Breeze chemiluminescence kit, following the manufacturer’s protocol (Invitrogen).

**Morphologic studies**

**Immunofluorescence.** Skin biopsy samples were taken (n = 3 per group) and snap-frozen in liquid nitrogen in a tissue-embedding medium. Frozen sections (8 μm) were soaked in acetone for 10 min, washed in PBS, and blocked with 4% BSA and 0.05% cold fish gelatin in PBS for 30 min. Slides were then incubated overnight at 4°C with CRAMP or mBD3 (Alpha Diagnostic) primary antibodies, followed by incubation with FITC-conjugated goat anti-rabbit secondary antibody for 40 min at room temperature. Slides were counterstained with propidium iodide and visualized on a Leica TCS-SP confocal microscope. Controls without primary antibodies showed no immunolabeling, and skin sections of CRAMP knockout mice served as controls.

**Electron microscopy.** Skin biopsies from PS and nonstressed mice were minced to less than 0.5 mm macrocidal growth phase (Amax = 0.8; 48 × 10^10 CFU/ml) of GAS NZ131 conjugated with 50 μl of sterile Cytoxid beads, which acts as a carrier, or Cytoxid beads alone (n = 6 per group). Lesions were photographed daily for 7 d, and lesion size was quantitated in digital micrographs.

**Immunoelectron microscopy.** Skin biopsies for immunoelectron microscopy were cut into 0.5-mm^3 pieces and microwave-fixed for 2.5 min in 0.1 M cacodylate buffer (pH 7.4, containing 0.1% sodium periodate, 0.6% L-lysine, and CaCl_2) at 37°C. Samples were postfixed in reduced osmium tetroxide (2% OsO_4 and 1.5% potassium ferrocyanide in 0.1 M cacodylate buffer, pH 7.4) for 2.5 min in the microwave at 37°C. Samples were then washed 3 times in double-distilled water; postfixed for 1 h in 2% aqueous uranyl acetate at 4°C; dehydrated in graded ethanol solutions and embedded in an Epon-epoxy mixture. Ultrathin sections were examined, with or without further lead citrate contrasting, using a Zeiss 10A electron microscope operated at 60 kV.

**Electron microscopy.** Skin biopsies for immunoelectron microscopy were cut into 0.5-mm^3 pieces and microwave-fixed for 2.5 min in 0.1 M cacodylate buffer (pH 7.4, containing 0.1% sodium periodate, 0.6% L-lysine, and CaCl_2) at 37°C. Samples were postfixed in reduced osmium tetroxide (2% OsO_4 and 1.5% potassium ferrocyanide in 0.1 M cacodylate buffer, pH 7.4) for 2.5 min in the microwave at 37°C. Samples were then washed 3 times in double-distilled water; postfixed for 1 h in 2% aqueous uranyl acetate at 4°C; dehydrated in graded ethanol solutions; transferred first to 1:1, then a 2:1, mixture of LR White resin (EMS) in 100% ethanol for 15 min each; and finally infiltrated in 100% LR White for 2 h (all steps at 4°C). Polymerization was carried out at 40°C under a vacuum for 2 d. Ultrathin sections were collected on Formvar-coated nickel grids. All immunolabeling steps were carried out at room temperature. Non-specific binding sites were blocked with 5% BSA, 5% normal goat serum, and 0.1% cold-water fish gelatin in PBS for 20 min, after which grids were washed 3 times for 5 min each in incubation buffer (0.1% Aurion BSA-c; EMS; in PBS). Primary antibodies (rabbit anti-CRAMP and rabbit anti-mBD3) were used at a 1:10 dilution in incubation buffer for 1 h. After 3 washes for 5 min each with incubation buffer, sections were incubated with goat anti-rabbit IgG, conjugated to 10 nm colloidal gold (Ted Pella Inc.) for 1 h. After secondary immunolabeling, grids were washed 6 times with incubation buffer followed by 3 washes with PBS, fixed in 2% glutaraldehyde in PBS for 5 min, followed by a final water wash for 30 s. Sections were examined by electron microscopy after contrasting with both 2% aqueous uranyl acetate and 0.6% lead citrate. Quantitation
of immunolabeling was carried out in coded, randomized micrographs (n = 10 each) from 4 different samples.

**Statistics**

Data were expressed as mean ± SEM. Statistical analyses were performed using paired and unpaired Student’s t tests. A P value less than 0.05 was considered significant.

**Acknowledgments**

These studies were supported by NIH grants AR19098, AR39448(PP), and AI059311 and by the Medical Research Service, Department of Veterans Affairs. K.M. Aberg was supported by an NIH postdoctoral fellowship (AR07175-28), Jens Schrøder (University of Kiel, Kiel, Germany) provided invaluable advice in preparing samples for Western blotting. We gratefully acknowledge the excellent editorial assistance of Joan Wakefield and Jerelyn Magnusson.

Received for publication February 6, 2007, and accepted in revised form July 16, 2007.

Address correspondence to: Peter M. Elias, Dermatology Service (190), VA Medical Center, 4150 Clement Street, San Francisco, California 94121, USA. Phone: (415) 750-2091; Fax: (415) 751-3927; E-mail: eliasp@derm.ucsf.edu.

Portions of this work were presented at the annual meeting of the Society for Investigative Dermatology in Philadelphia, Pennsylvania, USA, May 3–6, 2006, and published in abstract form.


